ASCO 2025
Featured articles
ATOMIC trial establishes new standard for adjuvant treatment in dMMR stage 3 colon cancer
Meet the expert: Prof. Marc Thill on the results of Datopotamab deruxtecan in the TROPION-Breast01 study
CONTENTS
Online First
Colorectal Cancer
Anlotinib non-inferior to bevacizumab in first-line treatment of mCRC
BREAKWATER makes waves in BRAF V600E-mutant mCRC treatment
ATOMIC trial establishes new standard for adjuvant treatment in dMMR stage 3 colon cancer
Postoperative ctDNA positivity signals poor prognosis in stage 3 colon cancer, despite chemotherapy escalation
Breast Cancer
Sacituzumab govitecan plus pembrolizumab outperforms chemotherapy in PD-L1+ metastatic TNBC
Vepdegestrant outperforms fulvestrant in ESR1-mutant advanced breast cancer
neoCARHP trial supports carboplatin omission in select HER2-positive early breast cancers
T-DXd plus pertuzumab sets first-line standard in HER2-positive metastatic breast cancer
ctDNA-guided switch to camizestrant delays progression in ESR1-mutated breast cancer
Ipatasertib-fulvestrant combination extends PFS after CDK4/6 inhibitor failure in ER+/HER2- metastatic breast cancer
Meet the expert: Prof. Marc Thill on the results of Datopotamab deruxtecan in the TROPION-Breast01 study
Gastric/Pancreatic Cancer
Elraglusib improves survival in untreated metastatic pancreatic cancer
TTFields therapy promotes survival benefit in unresectable pancreatic cancer
Neoadjuvant PAXG regimen doubles 3-year EFS over mFOLFIRINOX in resectable pancreatic cancer
DESTINY delivered: Trastuzumab deruxtecan extends survival in HER2-positive gastric cancer
MATTERHORN: Durvalumab plus FLOT significantly improves event-free survival in resectable gastric/GEJ adenocarcinoma
Satricabtagene autoleucel improves survival in advanced gastric and GEJ cancers
Genitourinary Cancer
AMPLITUDE boosts radiographic PFS with niraparib in HRR-mutated mCSPC
Double the impact with less BCG: Mitomycin combo maintains efficacy in NMIBC
Haematological Cancer
Rusfertide improved symptoms and quality-of-life in polycythaemia vera
Zilovertamab vedotin: early efficacy in relapsed or refractory DLBCL in combination with R-GemOx?
Glofitamab combination sustains long-term benefit in relapsed/refractory DLBCL
Long-term zanubrutinib efficacy in high-risk CLL/SLL patients with del(17p)
Lung Cancer
Patritumab deruxtecan shows PFS, but no OS-benefit in EGFR-mutant NSCLC
Neoadjuvant nivolumab improves overall survival in resectable NSCLC
Benmelstobart-anlotinib combination superior to pembrolizumab in advanced NSCLC
A chemotherapy-free second-line option for MET-amplified EGFR-mutant NSCLC
Consolidation therapy with benmelstobart in stage III NSCLC
Tarlatamab is better than chemotherapy in second-line SCLC
Head and Neck Cancer
Nivolumab addition to cisplatin-radiotherapy sets the first new post-operative standard for head-and-neck cancer in two decades
De-escalation: same survival, less vomiting
Antibody-drug conjugate outperforms chemotherapy
Skin Cancer
No added benefit of relatlimab in the adjuvant melanoma setting
Adjuvant BRAF/MEK-inhibition is safe and feasible in stage IIB/C BRAF V600-mutant melanoma
Adjuvant cemiplimab slashes recurrence risk in high-risk CSCC
Gynaecological Cancer
Timing of cytoreductive surgery does not impact overall survival in ovarian cancer
Dostarlimab (modestly) improves progression-free survival in advanced ovarian cancer
